Pharmaceutical care program for type 2 diabetes pa

Authors: Aline Oliveira Magalhães Mourão Wandiclécia Rodrigues Ferreira Maria Auxiliadora Parreiras Martins Adriano Max Moreira Reis Maria Ruth Gaede Carrillo Andrea Grabe Guimarães Lisiane Silveira Ev

Publish Date: 2012/11/18

Volume: 35, Issue: 1, Pages: 79-86

PDF Link

Abstract

Background Brazilians with type 2 diabetes require action to improve haemoglobin A1C levels considering the fact that approximately 73  of them have poor glycaemic control Evidence has shown the potential benefits of pharmaceutical care programs in type 2 diabetes patients Objective To evaluate the effect of a pharmaceutical care program on blood glucose blood pressure and lipid profile in hyperglycaemic patients undergoing drug treatment for type 2 diabetes Setting Six primary care units of the Brazilian public health system Ouro Preto Brazil Method An open randomised controlled clinical trial was conducted for 6 months Subjects aged 18 years or older who were using oral antidiabetic medications and presenting haemoglobin A1C levels ≥7  were randomly assigned to receive only usual health care or usual health care plus pharmaceutical intervention Main outcome measure Haemoglobin A1C Results A total of 129 subjects were enrolled and 100 patients completed the study Compared to the control group n = 50 the intervention group n = 50 showed a significant reduction of haemoglobin A1C −06 vs 07  p = 0001 fasting plasma glucose total cholesterol LDL cholesterol triglycerides and systolic blood pressure and a significant increase in HDL cholesterol and the use of lipidmodifying agents and platelet aggregation inhibitors Conclusions This study suggests that a pharmaceutical care program may provide important contributions to reduce haemoglobin A1C in type 2 diabetes patients Moreover the promotion of the rational use of drugs may be better achieved in a context of pharmaceutical care programs in Brazil

Keywords: